252 related articles for article (PubMed ID: 16690927)
1. A single administration of lentiviral vectors expressing either full-length human immunodeficiency virus 1 (HIV-1)(HXB2) Rev/Env or codon-optimized HIV-1(JR-FL) gp120 generates durable immune responses in mice.
Buffa V; Negri DRM; Leone P; Bona R; Borghi M; Bacigalupo I; Carlei D; Sgadari C; Ensoli B; Cara A
J Gen Virol; 2006 Jun; 87(Pt 6):1625-1634. PubMed ID: 16690927
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of a self-inactivating lentiviral vector expressing simian immunodeficiency virus gag for induction of specific immune responses in vitro and in vivo.
Buffa V; Negri DR; Leone P; Borghi M; Bona R; Michelini Z; Compagnoni D; Sgadari C; Ensoli B; Cara A
Viral Immunol; 2006; 19(4):690-701. PubMed ID: 17201664
[TBL] [Abstract][Full Text] [Related]
3. Cytotoxic T lymphocyte and helper T cell responses following HIV polynucleotide vaccination.
Shiver JW; Perry HC; Davies ME; Freed DC; Liu MA
Ann N Y Acad Sci; 1995 Nov; 772():198-208. PubMed ID: 8546393
[TBL] [Abstract][Full Text] [Related]
4. Cytotoxic T lymphocyte and antibody responses generated in rhesus monkeys immunized with retroviral vector-transduced fibroblasts expressing human immunodeficiency virus type-1 IIIB ENV/REV proteins.
Laube LS; Burrascano M; Dejesus CE; Howard BD; Johnson MA; Lee WT; Lynn AE; Peters G; Ronlov GS; Townsend KS
Hum Gene Ther; 1994 Jul; 5(7):853-62. PubMed ID: 7981310
[TBL] [Abstract][Full Text] [Related]
5. Replication-deficient recombinant adenoviruses expressing the human immunodeficiency virus Env antigen can induce both humoral and CTL immune responses in mice.
Bruce CB; Akrigg A; Sharpe SA; Hanke T; Wilkinson GWG; Cranage MP
J Gen Virol; 1999 Oct; 80 ( Pt 10)():2621-2628. PubMed ID: 10573155
[TBL] [Abstract][Full Text] [Related]
6. Prime-boost immunization schedules based on influenza virus and vaccinia virus vectors potentiate cellular immune responses against human immunodeficiency virus Env protein systemically and in the genitorectal draining lymph nodes.
Gherardi MM; Nájera JL; Pérez-Jiménez E; Guerra S; García-Sastre A; Esteban M
J Virol; 2003 Jun; 77(12):7048-57. PubMed ID: 12768024
[TBL] [Abstract][Full Text] [Related]
7. Successful immunization with a single injection of non-integrating lentiviral vector.
Negri DR; Michelini Z; Baroncelli S; Spada M; Vendetti S; Buffa V; Bona R; Leone P; Klotman ME; Cara A
Mol Ther; 2007 Sep; 15(9):1716-23. PubMed ID: 17593926
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity of attenuated vesicular stomatitis virus vectors expressing HIV type 1 Env and SIV Gag proteins: comparison of intranasal and intramuscular vaccination routes.
Egan MA; Chong SY; Rose NF; Megati S; Lopez KJ; Schadeck EB; Johnson JE; Masood A; Piacente P; Druilhet RE; Barras PW; Hasselschwert DL; Reilly P; Mishkin EM; Montefiori DC; Lewis MG; Clarke DK; Hendry RM; Marx PA; Eldridge JH; Udem SA; Israel ZR; Rose JK
AIDS Res Hum Retroviruses; 2004 Sep; 20(9):989-1004. PubMed ID: 15585086
[TBL] [Abstract][Full Text] [Related]
9. Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C.
Gómez CE; Nájera JL; Jiménez V; Bieler K; Wild J; Kostic L; Heidari S; Chen M; Frachette MJ; Pantaleo G; Wolf H; Liljeström P; Wagner R; Esteban M
Vaccine; 2007 Mar; 25(11):1969-92. PubMed ID: 17224219
[TBL] [Abstract][Full Text] [Related]
10. Construction and immunogenicity of Salmonella typhimurium vaccine vectors that express HIV-1 gp120.
Fouts TR; Tuskan RG; Chada S; Hone DM; Lewis GK
Vaccine; 1995 Dec; 13(17):1697-705. PubMed ID: 8719522
[TBL] [Abstract][Full Text] [Related]
11. Novel engineered HIV-1 East African Clade-A gp160 plasmid construct induces strong humoral and cell-mediated immune responses in vivo.
Muthumani K; Zhang D; Dayes NS; Hwang DS; Calarota SA; Choo AY; Boyer JD; Weiner DB
Virology; 2003 Sep; 314(1):134-46. PubMed ID: 14517067
[TBL] [Abstract][Full Text] [Related]
12. A qualitative progression in HIV type 1 glycoprotein 120-specific cytotoxic cellular and humoral immune responses in mice receiving a DNA-based glycoprotein 120 vaccine.
Fuller DH; Haynes JR
AIDS Res Hum Retroviruses; 1994 Nov; 10(11):1433-41. PubMed ID: 7888198
[TBL] [Abstract][Full Text] [Related]
13. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.
Abaitua F; Rodríguez JR; Garzón A; Rodríguez D; Esteban M
Virus Res; 2006 Mar; 116(1-2):11-20. PubMed ID: 16214252
[TBL] [Abstract][Full Text] [Related]
14. Effect of HIV-1 envelope cytoplasmic tail on adenovirus primed virus encoded virus-like particle immunizations.
Andersson AC; Ragonnaud E; Seaton KE; Sawant S; Folgori A; Colloca S; Labranche C; Montefiori DC; Tomaras GD; Holst PJ
Vaccine; 2016 Oct; 34(44):5344-5351. PubMed ID: 27633665
[TBL] [Abstract][Full Text] [Related]
15. Robust antigen-specific humoral immune responses to sublingually delivered adenoviral vectors encoding HIV-1 Env: association with mucoadhesion and efficient penetration of the sublingual barrier.
Domm W; Brooks L; Chung HL; Feng C; Bowers WJ; Watson G; McGrath JL; Dewhurst S
Vaccine; 2011 Sep; 29(40):7080-9. PubMed ID: 21801777
[TBL] [Abstract][Full Text] [Related]
16. Cross-clade protection induced by human immunodeficiency virus-1 DNA immunogens expressing consensus sequences of multiple genes and epitopes from subtypes A, B, C, and FGH.
Malm M; Rollman E; Ustav M; Hinkula J; Krohn K; Wahren B; Blazevic V
Viral Immunol; 2005; 18(4):678-88. PubMed ID: 16359234
[TBL] [Abstract][Full Text] [Related]
17. Construction, biological activity, and immunogenicity of synthetic envelope DNA vaccines based on a primary, CCR5-tropic, early HIV type 1 isolate (BX08) with human codons.
Corbet S; Vinner L; Hougaard DM; Bryder K; Nielsen HV; Nielsen C; Fomsgaard A
AIDS Res Hum Retroviruses; 2000 Dec; 16(18):1997-2008. PubMed ID: 11153083
[TBL] [Abstract][Full Text] [Related]
18. HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates.
García-Arriaza J; Perdiguero B; Heeney JL; Seaman MS; Montefiori DC; Yates NL; Tomaras GD; Ferrari G; Foulds KE; Roederer M; Self SG; Borate B; Gottardo R; Phogat S; Tartaglia J; Barnett SW; Burke B; Cristillo AD; Weiss DE; Lee C; Kibler KV; Jacobs BL; Wagner R; Ding S; Pantaleo G; Esteban M
J Virol; 2017 May; 91(9):. PubMed ID: 28179536
[TBL] [Abstract][Full Text] [Related]
19. Elicitation of neutralizing antibodies with DNA vaccines expressing soluble stabilized human immunodeficiency virus type 1 envelope glycoprotein trimers conjugated to C3d.
Bower JF; Yang X; Sodroski J; Ross TM
J Virol; 2004 May; 78(9):4710-9. PubMed ID: 15078953
[TBL] [Abstract][Full Text] [Related]
20. Retroviral vectors for HIV immunotherapy.
Warner JF; Jolly D; Mento S; Galpin J; Haubrich R; Merritt J
Ann N Y Acad Sci; 1995 Nov; 772():105-16. PubMed ID: 8546383
[No Abstract] [Full Text] [Related]
[Next] [New Search]
